創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/08/26 GEM208 A3 adenosine receptor (A3AR) agonist Liver cancer* NAFLD** Oral Small molecule Phase 3 in preparation* Phase 2 completed** ・A3AR is highly expressed in inflammatory and cancer cells. Specific agonists of A3AR induce apoptosis of cancer cells but not normal cells.
・Very good safety profile.
・An orphan drug status for hepatocellular carcinoma (HCC).
・In phase-2 study in HCC patients, it did not meet the primary endpoint (OS) but subgroup analysis of Child Pugh B patients showed a positive signal of efficacy for OS.
・In phase-2 study (vs placebo) in NAFLD/NASH, it met primary endpoint (liver enzyme) and reduced liver fat, fibrosis and steatosis.
問合せ
20/08/26 GEM207 A3 adenosine receptor (A3AR) agonist Rheumatoid arthritis (RA), Psoriasis Oral Small molecule Phase 3 ・A3AR is highly expressed in inflammatory and cancer cells. Specific agonists of A3AR induce apoptosis of inflammatory cells but not normal cells.
・Very good safety profile as 1st line therapy.
・In the pahse-2b study (monotherapy vs placebo) for12 weeks in naive RA patients, the endpoint was achieved.
・In the pahse-2/3 study (monotherapy vs placebo) in moderate to severe psoriasis patients, it did not meet the primary endpoint at 12 weeks, but at 32 week the improvement of PASI score was significant vs at 16 week.
・A phase-3 study (vs MTX) in moderate to severe RA and a phase-3 study (vs apremilast) are ongoing.
問合せ
20/08/24 GEM206 FLT3 Kinase Inhibitor Acute myeloblastic leukemia (AML) Oral Small molecule Preclinical - Novel chemical structure distinguished from known FLT3 inhibitors
- Highly potent against FLT3 and FLT3 mutants (overcome FLT3-TKD mutation mediated drug resistant)
- Highly selective
- Monotherapy & orally active
- Well-tolerance in preclinical tox study
- GLP tox study is in progress.
問合せ
20/08/24 GEM205 Anti-Mesothelin (MSLN) Antibody-Drug Conjugate (ADC) Cancer (Pancreatic Cancer, Ovarian Cancer etc.) Injection Antibody Preclinical - Mesothelin is a differentiation antigen overexpressed in many solid tumors
- GEM205 showed great tumor growth inhibition (>90%) in animal model without body weight loss.
- GEM205 also showed great efficacy in large tumor model (>500 mm3).
- Self-owned I4 technology was applied in GEM205.
- GEM205 showed uniform DAR (4), high affinity, good cytotoxicity.
問合せ
20/08/24 GEM192 Selective PI3Kα inhibitor Slow-flow vascular malformations Oral Small molecule Phase 1 Slow-flow vascular malformations including venous malformation, lymphatic malformation, Klippel-Trenaunay syndrome is abnormal clustering of blood vessels that occurs in children or young adults and are caused by PI3K pathway GOF mutation. By selectively inhibiting PI3Kα isoform, GEM192 inhibits angiogenesis, but not immune function resulting in better therapeutic effects and lower infectious risk. Phase 1/2 data for another indication demonstrate a favorable tolerability profile. Clinical development to be pursued with new pediatric formulation. 問合せ
20/08/24 GEM185 GLP-1/GIP dual agonist Obesity, diabetes s.c. Peptide Phase 1 GEM185 is an injectable (QD) dual agonist for GLP-1R and GIPR. Preclinical studies have shown that GEM185 is more effective in improving diabetes and obesity than GLP-1R agonism only. In addition, GEM185 has been shown to improve liver parameters in diabetic and obesity conditions in preclinical research. Hence, GEM185 may be superior to the GLP-1R agonist in improving diabetes, obesity, and non-alcoholic steatohepatitis (NASH). In a preclinical study, GEM185 showed better efficacy in improving glycemic control and an almost same efficacy in decreasing body weight compared to tirzepatide, a Lilly’s Ph3 program. A long-acting formulation, which is likely to maximize its therapeutic efficacy, are under development. A phase 1 study (first-in-human study), starting in 2020, is being organized in the UK. 問合せ
20/08/12 GEM204 Multi-molecular targeting including the Wnt/𝛽-catenin pathway Hair loss, Andogenetic alopecia, Telogen effluvium, Senescent alopecia Topical and/or oral Plant extracts Commercial GEM204 is a comprehensive solution for the treatment of hair loss, targeting more than 21 hair regulating molecular pathways to promote hair growth and inhibit hair loss. Market approval and full scientific dossier available with clinical trials in women and men of all hair loss patterns, hair types and skin types. 問合せ
20/08/10 GEM203 FXR agonist and 5-HTR2A antagonist NAFLD, Type 2 diabetes, obesity, dyslipidemia and hypertension Oral Small molecule Preclinical First in class single molecule having both FXR agonistic and 5-HTR2A antagonistic actions.

In DIO mice, GEM203 reduced hyperglycemia, hyperinsulinemia, insulin resistance and liver lipid contents to similar or greater extent vs metformin. GEM203 reduced the body excess weight while metformin did not.
In NASH model mice, GEM203 reduced liver excess weight, TG and TC contents, plasma ALT and AST, inflammation and collagen gene expression in the liver.

Strong IP portfolio with long expiry dates granted in major markets.
問合せ
20/08/05 GEM202 Somatostatin receptor subtype 5 (SSTR5) antagonist Type 2 diabetes, Gallstone, Primary sclerosing cholangitis (PSC), Inflammatory bowel disease (IBD), short bowel syndrome (SBS) Oral Small molecule IND ready SSTR5 is primarily expressed in pancreatic ß-cells and enteroendocrine cells, and its ligand, somatostatin, negatively regulates the secretion of insulin and gut hormones (GLP-1, GLP-2, PYY, etc.). GEM202 is a selective SSTR5 antagonist and is unique owing to its dual action of elevating these hormone secretions and increasing insulin sensitivity, thereby improves glycemic control in obese and diabetic mice. In addition, GEM202 is effective in stimulating gallbladder motility and increasing bile flow, accounting for its therapeutic effects in animal models of gallstones and PSC. Thus, an additional potential application involves treatment of hepatobiliary diseases. Patents have been filed globally. 問合せ
20/08/01 GEM201 mRNA Vaccine Platform technology. Production of S-Protient with Immune-modulators in one construct Coronavirus (COVID-19); Broader Vaccine Platform i.v. Drug Delivery, Cell therapy Preclinical GEM201 utilizes TGEM055 technology loaded with antigenetic proteins as a mRNA Vaccine Platform
- Produce functional antigenetic protiens in Lymphatic organs
- Localized antigen induction at high intracellular amounts where antigen presenting cells aggregate. Co-delivery of potent Immune-modulators (GM-CSF, IL-12, etc) sumultaneously
- GEM201 is a vaccine platform
- GEM201 is critical for vaccination of elderly and immune suppresed populati
問合せ